BEIJING--Sinovac Biotech Ltd. ( `Sinovac` or the ` Company`)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced an update to its previously announced partnership with Butantan, a leading Brazilian producer of immunobiologic products and vaccines. On July 3, 2020, the Brazilian National Regulatory Agency, Anvisa, granted approval to a phase III clinical trial sponsored by Instituto Butantan to test efficacy and safety of the inactivated COVID-19 vaccine developed by Sinovac Life Sciences Co., Ltd. ( or `Sinovac LS`, previously known as Sinovac Research and Development Co., Ltd. or `Sinovac R&D`), a wholly owned subsidiary of the Company, in Brazil. This...
|
